Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alison Luckey

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
BMJ Open|February 4, 2022
Factors associated with recruitment success in the phase 2a study of aztreonam-avibactam development programme: a descriptive qualitative analysis among sites in SpainRosa M Jimenez-Rodriguez, Guillermo Martín-Gutiérrez, Silvia Jiménez-Jorge, et al.
The Lancet. Infectious Diseases|October 10, 2024
Aztreonam-avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trialYehuda Carmeli, José Miguel Cisneros, Mical Paul, et al.
Lancet (London, England)|December 14, 2025
Zoliflodacin versus ceftriaxone plus azithromycin for treatment of uncomplicated urogenital gonorrhoea: an international, randomised, controlled, open-label, phase 3, non-inferiority clinical trialAlison Luckey, Manica Balasegaram, Lindley A Barbee, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
BMJ Open|February 4, 2022
Factors associated with recruitment success in the phase 2a study of aztreonam-avibactam development programme: a descriptive qualitative analysis among sites in SpainRosa M Jimenez-Rodriguez, Guillermo Martín-Gutiérrez, Silvia Jiménez-Jorge, et al.
The Lancet. Infectious Diseases|October 10, 2024
Aztreonam-avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trialYehuda Carmeli, José Miguel Cisneros, Mical Paul, et al.
Lancet (London, England)|December 14, 2025
Zoliflodacin versus ceftriaxone plus azithromycin for treatment of uncomplicated urogenital gonorrhoea: an international, randomised, controlled, open-label, phase 3, non-inferiority clinical trialAlison Luckey, Manica Balasegaram, Lindley A Barbee, et al.
Pageof 2